Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.90USD
4:00pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.90
Open
$2.88
Day's High
$2.97
Day's Low
$2.88
Volume
79,813
Avg. Vol
147,662
52-wk High
$4.51
52-wk Low
$2.20

Chart for

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $294.45
Shares Outstanding(Mil.): 102.60
Dividend: --
Yield (%): --

Financials

  CPRX.OQ Industry Sector
P/E (TTM): -- 95.67 30.17
EPS (TTM): -0.22 -- --
ROI: -40.31 3.33 12.67
ROE: -40.43 2.31 14.86

BRIEF-Catalyst Pharmaceuticals Reports Q1 GAAP Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody Positive Myasthenia Gravis

* CATALYST PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 TRIAL OF FIRDAPSE® IN MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS Source text for Eikon: Further company coverage:

Apr 19 2018

BRIEF-Catalyst Pharma Submits NDA For Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR FIRDAPSE® FOR TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME

Mar 29 2018

BRIEF-Catalyst Pharmaceuticals Announces Q4 Gaap Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 14 2018

Earnings vs. Estimates